login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ENLIVEX THERAPEUTICS LTD (ENLV) Stock News
USA
- NASDAQ:ENLV -
IL0011319527
-
Common Stock
1.05
USD
0 (0%)
Last: 10/31/2025, 8:00:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ENLV Latest News, Press Relases and Analysis
All
Press Releases
4 days ago - By: Enlivex Therapeutics Ltd
Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025
4 days ago - By: Enlivex Therapeutics Ltd
Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025
a month ago - By: ACCESS Newswire
- Mentions:
LTRN
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
a month ago - By: Enlivex Therapeutics Ltd
D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program
a month ago - By: Enlivex Therapeutics Ltd
D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program
a month ago - By: ACCESS Newswire
- Mentions:
SXTP
Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2 months ago - By: Enlivex Therapeutics Ltd
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results
2 months ago - By: Enlivex Therapeutics Ltd
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
2 months ago - By: Benzinga
- Mentions:
TNXP
SNGX
USBC
BNR
...
12 Health Care Stocks Moving In Monday's Intraday Session
2 months ago - By: Enlivex Therapeutics Ltd
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
2 months ago - By: Enlivex Therapeutics Ltd
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
3 months ago - By: Enlivex Therapeutics Ltd
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
3 months ago - By: Enlivex Therapeutics Ltd
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
3 months ago - By: Enlivex Therapeutics Ltd
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data
3 months ago - By: Enlivex Therapeutics Ltd
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data
5 months ago - By: ACCESS Newswire
- Mentions:
FMST
Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
5 months ago - By: Enlivex Therapeutics Ltd
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
5 months ago - By: Enlivex Therapeutics Ltd
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
5 months ago - By: Enlivex Therapeutics Ltd
Enlivex Selected to Present at Israeli BioMed 2025 Conference
6 months ago - By: Enlivex Therapeutics Ltd
Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress
6 months ago - By: Enlivex Therapeutics Ltd
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis
6 months ago - By: Enlivex Therapeutics Ltd
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis
7 months ago - By: Enlivex Therapeutics Ltd
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
8 months ago - By: Enlivex Therapeutics Ltd
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
8 months ago - By: Enlivex Therapeutics Ltd
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
8 months ago - By: Enlivex Therapeutics Ltd
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
8 months ago - By: Enlivex Therapeutics Ltd
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis
8 months ago - By: Enlivex Therapeutics Ltd
Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis
8 months ago - By: Enlivex Therapeutics Ltd
Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis
9 months ago - By: Enlivex Therapeutics Ltd
Enlivex Issues Urgent Statement on Fraudulent News Dissemination
9 months ago - By: Enlivex Therapeutics Ltd
Enlivex Issues Urgent Statement on Fraudulent News Dissemination
9 months ago - By: ACCESS Newswire
- Mentions:
ASPI
NVA
BFRG
GRRR
RedChip Announces Webinar to Teach Investors How to Use RedChat, a Revolutionary AI Chatbot for Small-Cap Stock Analysis
a year ago - By: Enlivex Therapeutics Ltd
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
a year ago - By: Enlivex Therapeutics Ltd
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
a year ago - By: Enlivex Therapeutics Ltd
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Please enable JavaScript to continue using this application.